Abstract
Development of targeted radionuclide therapy with 90Y labeled antibodies and peptides has gained momentum in the past decade due to the successes of 90Y-ibritumomab tiuxetan and 90Y-DOTA-Phe1-Tyr3-octreotide in treatment of cancer. 90Y is a pure β--emitter and cannot be imaged for patient-specific dosimetry which is essential for pre-therapeutic treatment planning and accurate absorbed dose estimation in individual patients to mitigate radiation related risks. This review article describes the utility of 86Y, a positron emitter (33%) with a 14.7-h half-life that can be imaged by positron emission tomography and used as an isotopically matched surrogate radionuclide for 90Y radiation doses estimations. This review discusses various aspects involved in the development of 86Y labeled radiopharmaceuticals with the specific emphasis on the radiochemistry and biological applications with antibodies and peptides.
Keywords: PET imaging, radiochemistry, 90Y, 86Y, bioconjugate chemistry, peptides, antibodies, positron emitter, Radiopharmaceuticals, targeted radionuclide therapy
Medicinal Chemistry
Title: 86Y Based PET Radiopharmaceuticals: Radiochemistry and Biological Applications
Volume: 7 Issue: 5
Author(s): Tapan K. Nayak and Martin W. Brechbiel
Affiliation:
Keywords: PET imaging, radiochemistry, 90Y, 86Y, bioconjugate chemistry, peptides, antibodies, positron emitter, Radiopharmaceuticals, targeted radionuclide therapy
Abstract: Development of targeted radionuclide therapy with 90Y labeled antibodies and peptides has gained momentum in the past decade due to the successes of 90Y-ibritumomab tiuxetan and 90Y-DOTA-Phe1-Tyr3-octreotide in treatment of cancer. 90Y is a pure β--emitter and cannot be imaged for patient-specific dosimetry which is essential for pre-therapeutic treatment planning and accurate absorbed dose estimation in individual patients to mitigate radiation related risks. This review article describes the utility of 86Y, a positron emitter (33%) with a 14.7-h half-life that can be imaged by positron emission tomography and used as an isotopically matched surrogate radionuclide for 90Y radiation doses estimations. This review discusses various aspects involved in the development of 86Y labeled radiopharmaceuticals with the specific emphasis on the radiochemistry and biological applications with antibodies and peptides.
Export Options
About this article
Cite this article as:
K. Nayak Tapan and W. Brechbiel Martin, 86Y Based PET Radiopharmaceuticals: Radiochemistry and Biological Applications, Medicinal Chemistry 2011; 7 (5) . https://dx.doi.org/10.2174/157340611796799249
DOI https://dx.doi.org/10.2174/157340611796799249 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances Towards The Discovery of GPR55 Ligands
Current Medicinal Chemistry Expression and Functions of Vasoactive Substances Regulated by Hypoxia-Inducible Factor-1 in Chronic Hypoxemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Manipulating Intracellular Ca2+ Signals to Stimulate Therapeutic Angiogenesis in Cardiovascular Disorders
Current Pharmaceutical Biotechnology Recent Studies of QSAR on Inhibitors of Estrogen Receptor and Human Eosinophil Phosphodiesterase
Current Computer-Aided Drug Design High-component Reactions (HCRs): An Overview of MCRs Containing Seven or More Components as Versatile Tools in Organic Synthesis
Current Organic Synthesis Development and Comparison of Nanosponge and Niosome based Gel for the Topical Delivery of Tazarotene
Pharmaceutical Nanotechnology Biochemistry and Physiology of Anabolic Androgenic Steroids Doping
Mini-Reviews in Medicinal Chemistry Absorption, Pharmacokinetics and Disposition of Biodegradable Nanoscale Preparations
Current Drug Metabolism Diterpenoids- Potential Chemopreventive and Chemotherapeutic Agents in Leukemia
Current Pharmaceutical Biotechnology Vascular Toxicity of Chemotherapeutic Agents
Current Vascular Pharmacology Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis
Current Drug Targets Insights into the Targeting Potential of Thymoquinone for Therapeutic Intervention Against Triple-negative Breast Cancer
Current Drug Targets Controlled Drug Delivery Using Microdevices
Current Pharmaceutical Biotechnology Collaboration of Heat Shock Protein 70 and Stress-induced NKG2D Ligands in the Activation of NK Cells against Tumors
Current Immunology Reviews (Discontinued) Drug Delivery Systems for Prevention and Treatment of Osteoporotic Fracture
Current Drug Targets Advances in Immunotherapy of Chronic Myeloid Leukemia CML
Current Cancer Drug Targets Aberrant Activation of Arachidonic Acid and Eicosanoid Pathways-Targets for Treating Prostate Cancer
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Immune Checkpoint Inhibitors: Basics and Challenges
Current Medicinal Chemistry Antibodies as Crypts of Antiinfective and Antitumor Peptides
Current Medicinal Chemistry ADAM19/Adamalysin 19 Structure, Function, and Role as a Putative Target in Tumors and Inflammatory Diseases
Current Pharmaceutical Design